Elective lower segment caesarean section
Conditions
Interventions
Trade Name: Syntocinon
Product Name: Syntocinon
Pharmaceutical Form: Concentrate for solution for infusion
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the plac
Sponsors
Coombe Women's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Healthy women at term (>36 weeks) with a singleton pregnancy booked for an elective caesarean section Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Placenta praevia; multiple pregnancy; known coagulopathy; current anti-coagulant therapy; thrombocytopenia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate whether an additional oxytocin infusion reduces blood loss at caesarean section;Secondary Objective: To quantify side effects of an oxytocin infusion at caesrean section;Primary end point(s): Estimated mean operative blood loss; use of additional uterotonic agent; incidence of side effects | — |
Countries
Ireland
Outcome results
None listed